IGF2BP2 and esophageal adenocarcinoma: Although IGF2BP2 has been shown in the literature to be highly expressed in high-grade dysplasia (HGD) or Barrett’s esophagus, which are considered to be precancerous lesions of EC [34,35], it is unknown whether the targeted peptide can be used for the diagnosis of precancerous lesions.